良性前列腺增生症的药物治疗与评价  

Evaluation on Drug Treatment for Benign Prostatic Hyperplasia

作　　者：范治国 刘航[2] 

机构地区：[1]重庆北部新区第一人民医院药剂科,重庆401121 [2]重庆医科大学附属第一医院泌尿外科,重庆400016

出　　处：《中国医院用药评价与分析》2012年第11期964-966,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:伴随老龄社会深化和人数增加,属于老年医学范畴的一组泌尿系统疾病(良性前列腺增生症、前列腺癌、前列腺炎、勃起功能障碍、早泄和膀胱过度活动症)的治疗正日益受到关注,用药情况呈明显上升趋势,本文对抗前列腺增生药的临床应用进行分析评价。方法:采用国内外文献分析方法。结果与结论:抗良性前列腺增生症药的合理和安全应用尤为重要。OBJECTIVE：With the deepening of ageing society and increase of aging population,the treatment for a group of urinary system diseases belonging to gereology including benign prostatic hyperplasia,prostatic cancer,prostatitis,erectile dysfunction,prospermia and overactive bladder has attracted considerable attention.The use of the drugs for these diseases showed a sharp increase.In this paper,we evaluated the clinical use of the drugs against prostatic hyperplasia.METHODS：The pertinent literature both at home and abroad was analyzed.RESULTS CONCLUSION：It is especially important to achieve rational use of drugs against benign prostatic hyperplasia.

关 键 词：良性前列腺增生症 5Α还原酶抑制剂 Α受体阻断剂 合理用药 

分 类 号：R983[医药卫生—药品]